Neuron23, a biotech company has announced Phase 2 trial of its drug NEU-411 to target people with early-stage PD driven by LRRK2

Neuron23, a biotech company focused on precision medicine, has announced plans for a groundbreaking Phase 2 trial of its drug NEU-411. The trial, set to start in early 2025, will target people with early-stage Parkinson’s disease (PD) driven by a specific genetic factor called LRRK2. This innovative approach could significantly change how the disease is treated by slowing its progression rather than just managing symptoms. What is NEU-411? NEU-411 is a new drug designed to block the activity of LRRK2, a protein linked to Parkinson’s in both familial and non-familial cases. In earlier trials, NEU-411 was shown to be safe, well-tolerated, and effective at targeting the LRRK2 pathway in healthy volunteers. By targeting the root cause of disease progression in LRRK2-driven Parkinson’s, NEU-411 offers hope for a more precise and effective treatment. Why LRRK2 Matters LRRK2 gene mutations are the most common genetic cause of Parkinson’s disease, affecting about 2% of patients. However, up to 30% of all Parkinson’s cases may involve LRRK2 activity, even in people without the mutation. By focusing on this pathway, NEU-411 has the potential to benefit a broader group of Parkinson’s patients. The NEULARK Trial The global NEULARK trial will test NEU-411 in people with early-stage Parkinson’s to evaluate its safety and effectiveness. Unlike traditional trials, this study will use advanced technology to identify participants who are most likely to respond to the treatment. Key innovations include: Precision Screening: Collaborations with companies like QIAGEN and Quest Diagnostics will help identify patients with genetic markers for LRRK2-driven Parkinson’s through saliva tests and genetic sequencing. Digital Biomarkers: Roche-developed smartphone software will track symptoms like tremors and slowed movements in real-time, offering a more detailed view of disease progression than standard clinical assessments. A New Era for Parkinson’s Treatment Dr. Nancy Stagliano, CEO of Neuron23, called the trial a “new dawn” for Parkinson’s research. "Current treatments only manage symptoms. NEU-411 aims to address the underlying cause of disease progression for LRRK2-driven Parkinson’s," she said. By integrating cutting-edge genetic testing and digital tracking, this trial could redefine how Parkinson’s is studied and treated, potentially offering a path toward slowing or halting the disease. Neuron23’s NEULARK trial represents an exciting step forward for both Parkinson’s research and precision medicine, offering hope for patients and paving the way for future innovations.